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The opioid receptor, with which potent prescription analgesic 
morphine interacts, is one of the promising drug targets.  Opioid 
receptors are classified into three major types, MOR (µ opioid 
receptor), DOR (δ opioid receptor), and KOR (κ opioid receptor). 
For several decades, medicinal chemists have focused on 
development of selective agonists and antagonists for each opioid 
receptor type. The message-address concept is a useful guideline 
for design of type selective opioid ligands.1 For example, DOR 
antagonists such as NTI,2 NTB,3  BNTX,4 and SB-205588,5 DOR 
agonists such as TAN-67,6 SB-219825,5 NS-28,7 and KNT-127,8 
KOR antagonists such as nor-BNI9 and 5’-GNTI,10 and the KOR 
agonist nalfurafine11,12 were designed and synthesized according 
to this concept (Fig. 1). The message part plays an important role 
in exerting opioid functions. In contrast to the KOR ligands, 
which have the 4,5-epoxymorphinan functionality as the common 
message structure, the DOR ligands possess various message 
structures, including 4,5-epoxymorphinan, morphinan, and 4a-
phenyldecahydroisoquinoline structures. Recently, we found 
propellane 1 (Fig. 2) as a novel message skeleton.13 The 
propellane 1 bound to the MOR, DOR, and KOR with binding 
affinities (Ki)  of 58.2 nM, 448 nM, and 17.4 nM, respectively. 
These results prompted us to develop novel ligands with the 
propellane skeleton. However, indolopropellane 2 (Fig. 3) was 
reported to show almost no affinity for opioid receptors14 
although 2 has not only a propellane skeleton as a message 
structure but also an indole moiety as a possible DOR address 
part like the selective DOR antagonist NTI.1,2 To explain these 
observations, we developed the working hypothesis that 2 could 
adopt two different conformations, bent and extended (Fig. 3). 
The extended conformer, which resembles the stable 
conformation of NTI, could bind to the DOR whereas the bent 
conformer could not. Indeed the real binding conformation of 
NTI unveiled by the X-ray crystallographic analysis of the NTI-
DOR complex15 is an extended form (Fig. 4). The lack of binding 
of 2 to the DOR may be derived from the adoption of the bent 
conformer, which may be the more stable form. 
This working hypothesis suggests that the introduction of an 
additional pharmacophore into the structure of 2, which can 
interact with the DOR to stabilize the ligand-DOR complex, 
would enhance the binding affinity to the DOR. In the course of 
developing the selective DOR agonist TAN-67,6 we assumed an 
interaction between the quinoline nitrogen and the DOR and that 
the interaction would trigger the precise conformational change 
of the DOR to exert the DOR agonist activity. On the basis of the 
above consideration, we designed quinolinopropellane 3a (Fig. 3) 
as a DOR agonist which contains an additional possible 
pharmacophoric moiety like TAN-67. Herein, we report the 
conformational analyses of indolo- and quinolinopropellanes 2 
and 3a and the evaluation of the binding free energies of the 
ligands to the DOR. We also describe the synthesis of the 
designed quinolinopropellane derivatives 3a–d and their in vitro 
profiles.
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Indolopropellane 2 was reported to show almost no binding affinity to the δ opioid receptor 
(DOR) in spite of the fact that 2 has both the propellane fundamental skeleton (message part) 
with binding ability to the opioid receptors and a possible DOR address structure (indole 
moiety). We developed the working hypothesis that almost no binding affinity of 2 to the DOR 
would be derived from its possibly stable bent conformer. To enable the propellane skeleton to 
adopt an extended conformation which would reasonably interact with the DOR, 
quinolinopropellanes 3a–d were designed which had an additional pharmacophore, quinoline 
nitrogen. The calculated binding free energies of ligand-DOR complexes strongly supported our 
working hypothesis. The synthesized quinolinopropellane 3a was a selective DOR full agonist, 
confirming our working hypothesis and the results of in silico investigation. 
2009 Elsevier Ltd. All rights reserved. 
Keywords: 
Opioid  
DOR 
Propellane structure 
Binding mode  
Binding free energy  
This is an author version based on a template by Elsevier.
Figure 1. Structures of DOR antagonists, DOR agonists, KOR antagonists, KOR agonist. The message structures of these ligands are indicated in red. 
Figure 2. Structure of propellane 1. 
Figure 3. Structures of indolopropellane 2, quinolinopropellane 3a, and the 
bent and extended forms of 2. 
Figure 4. The binding mode of NTI observed in the X-ray structure of the 
NTI-DOR complex. 
Figure 5. The superimpositions of the low-energy conformers of NTI, 2, and 
3a. 
First, to investigate our proposal related to the bent and 
extended conformers of indolo- and quinolinopropellanes 2 and 
3a, we performed conformational analyses of NTI, 2, and 3a 
using Conformational Analyzer with Molecular Dynamics And 
Sampling (CAMDAS) 2.1 program.16 When the low-energy 
conformers of NTI, 2, and 3a (those within 2.5 kcal/mol of the 
global minimum) were superimposed (Fig. 5), we found that the 
low-energy conformers of  both 2 and 3a adopted the bent form, 
while those of NTI had the extended form, as expected. The 
extended forms of 2 and 3a roughly appeared at the energy 
difference of 3–5 kcal/mol from the global minimum.  
Next, the binding modes of 2 and 3a with the DOR and their 
binding free energies (∆Gbind values) were examined by using a 
combination method of the molecular-docking calculation17 and 
the molecular mechanics Generalized-Born surface area (MM-
GBSA) free energy analysis18,19. The resulting binding modes of 
2 and 3a are displayed in Figure 6, and their calculated ∆Gbind 
values are given in Table 1. Indolopropellane 2 was found to 
bind with the DOR in its extended form (Fig. 6A). This result 
strongly supported our working hypothesis that the extremely 
low affinity of 2 to the DOR may be due to the fact that 2 could 
not bind to the DOR when the ligand was in the low-energy bent 
form. In other words, the binding of 2 to the DOR would require 
a considerable energy penalty to adopt the high-energy extended 
form, which is suited to bind to the DOR as shown in the crystal 
structure of the NTI-DOR complex15 (Fig. 4). On the other hand, 
the binding mode of quinolinopropellane 3a (Fig. 6B) suggested 
that the extended form of 3a could also bind to the DOR20.  
Interestingly, we found that the lone electron pair on the nitrogen 
atom of the quinoline ring in 3a could form a hydrogen bonding 
interaction with the NH3+ of the Lys214 residue.  A similar 
hydrogen bond was not observed in the 2-DOR complex,
Table 1. Energy contributions (kcal/mol) to the binding free energy of 2 and 3a to the DOR.
Contribution 2 3a Differencea 
∆Eintb 3.19 2.80 0.39 
∆EVDWc –50.03 –48.59 –1.44 
∆Eelecd –11.93 –25.47 13.54 
∆GGBe 11.06 13.99 –2.93 
∆GSAf –6.28 –8.15 1.87 
∆Gbindg –53.99 –65.42 11.43 
a Differences of energy contributions of 2 and 3a.  
b Internal contributions from bond, angle, dihedral terms.  
c Nonbonded van der Waals.  
d Nonbonded electrostatics.  
e Electrostatic component to solvation.  
f Nonpolar component to solvation.  
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Figure 6. The binding modes of 2 (A) and 3a (B) with the DOR determined 
by our docking procedure. Hydrogen-bonding interactions are indicated by 
red dashed lines. 
 
because 2 possessed the indole ring which lacks a lone electron 
pair. Due to the additional hydrogen bonding interaction, the 
electrostatic interaction (∆Eelec) of 3a with the DOR was 
suggested to be much greater than that of 2 (Table 1). This 
situation inevitably led to a much better ∆Gbind value for 3a. 
Taken together, the above observations suggested that the 
additional hydrogen bonding interaction in the 3a-DOR complex 
might compensate for any energy penalty, allowing 3a to adopt 
the high-energy extended form upon binding. The obtained 
binding mode of quinolinopropellane 3a with the DOR included 
the hydrogen bonding with the Lys214 residue, whereas a 
corresponding interaction with the Lys214 residue was not 
observed in the crystal structure of the NTI (DOR antagonist)-
DOR complex.15 In the course of DOR agonist TAN-67 
discovery, the hydrogen bonding with the DOR was proposed to 
Scheme 1. Synthesis of quinolinopropellane 3a. Reagents and conditions: (a) 
2-Aminobenzaldehyde, MeSO3H, EtOH, reflux; (b) HCl∙Pyridine, 180 ˚C. 
Scheme 2. Synthesis of quinolinopropellanes 3b–d. Reagents and conditions: 
(a) (i) Troc-Cl, K2CO3, CH2Cl2, rt; (ii) Zn, AcOH, rt; (b) (i) 2-
Aminobenzaldehyde, MeSO3H, EtOH, reflux; (ii) 1-Acetoxy-1-
cyclopropanecarboxylic acid, EDCI∙HCl, DMAP, DMF, rt; (iii) LiAlH4, 
H2SO4, THF, rt; (c) (i) 2-Aminobenzaldehyde, MeSO3H, EtOH, reflux; (ii) 
BnBr, K2CO3, DMF, rt; (d) (i) MeI, Et3N, CH2Cl2, rt; (ii) 2-
Aminobenzaldehyde, MeSO3H, EtOH, reflux; (e) BBr3, CH2Cl2, 0 ˚C to rt; 
(f) HCl∙Pyridine, 180 ˚C. 
 
be important in producing the DOR agonist activity.6 Therefore, 
quinolinopropellane 3a was expected to produce DOR agonism. 
 To confirm the in silico outcomes, we synthesized 
quinolinopropellanes 3a–d. A quinolone moiety was constructed 
by the reaction of compound 4a with 2-aminobenzaldehyde in 
the presence of methanesulfonic acid (Friedländer quinoline 
synthesis21), followed by demethylation of the O-Me group in 5a 
to provide 3a (Scheme 1). Via nor-compound 4b obtained from 
4a by a reaction with Troc-Cl and subsequent treatment with 
Zn/AcOH, the conversion of N-substituents was carried out by 
two methods: 1) a Friedländer quinoline synthesis and followed 
by amidation with carboxylic acid and reduction of the obtained 
amide by alane,22 and 2) a sequential Friedländer quinoline 
synthesis and alkylation (Scheme 2).  
The binding affinities of the prepared quinolinopropellanes 
3a–d to the opioid receptors were evaluated by competitive 
Table 2. Binding affinities of quinolinopropellanes 3a–d to the opioid receptorsa 
Compound R Ki (nM) Selectivity MORb DORc KORd MOR/DOR KOR/DOR 
3a CPM 112 0.941 84.6 119 89.9 
3b 1-OH-CPM 415 1.10 879 378 801 
3c Bn 76.3 31.6 594 2.42 18.8 
3d Me 3.06 1.88 195 1.63 104 
a Binding assays were carried out in duplicate.  
b [3H] DAMGO was used.  
c [3H] DPDPE was used.  
d [3H] U-69,593 was used.  
e CPM: cyclopropylmethyl 
 
binding assays (Table 2). As we expected, all the tested 
quinolinopropellanes 3a–d exhibited high binding affinities and 
selectivities for the DOR. Quinolinopropellane 3a with the N-
cyclopropylmethyl group had the highest binding affinity for the 
DOR, while N-(1-hydroxycyclopropylmethyl) derivative 3b 
showed the highest selectivity for the DOR, although its binding 
affinity for the DOR was slightly decreased compared with that 
of 3a. Although a propellane 1 derivative with the N-methyl 
substituent was reported to be a strong binder to the MOR (Ki = 
3.6 nM) with 122- and 71-fold greater selectivities over the DOR 
and KOR,13 respectively, N-methylquinolinopropellane 3d 
exerted low but evident selectivity for the DOR. 
We next assessed the functional activities of a selected 
compound 3a, which exhibited the highest binding affinity for 
the DOR, by [35S]GTPγS binding assays. As we expected, 3a 
exhibited DOR full agonist activity (EC50 (DOR) = 2.50 nM, Emax 
(DOR) = 88%, EC50 (MOR) = 197 nM, Emax (MOR) = 56%, EC50 
(KOR) = 836 nM, Emax (KOR) = 57%). The functional DOR 
selectivities of 3a were comparable to or higher than its binding 
DOR selectivities (EC50 ratio: MOR/DOR = 78.8, KOR/DOR = 
334). The outcomes of in vitro evaluations strongly supported our 
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working hypothesis and the in silico experimental results. 
Moreover, these observations suggest that the hydrogen bonding 
interaction between a ligand and the Lys214 residue in the DOR 
plays a crucial role in not only obtaining strong binding ability 
but also exerting DOR agonist activity.  
In conclusion, we have developed the working hypothesis that 
almost no binding affinity of indolopropellane 2 to the DOR 
would be derived from its possibly more stable bent conformer. 
To enable the propellane skeleton to adopt an extended 
conformation, which could reasonably be expected to interact 
with the DOR, quinolinopropellanes 3a–d were designed which 
had an additional pharmacophore, the quinoline nitrogen. The 
calculated binding free energies of ligand-DOR complexes 
strongly supported our working hypothesis. The synthesized 
quinolinopropellane 3a was a selective DOR full agonist, 
confirming our working hypothesis and the results of in silico 
investigation. 
Acknowledgments 
We acknowledge the financial supports from Shorai 
Foundation for Science, Uehara Memorial Foundation and 
Adaptable and Seamless Technology Transfer Program 
through target-driven R&D, JST (AS2315040G) (to H.N.,  
S.H., T.I., T.N., and H.F.). We also acknowledge the Institute of 
Instrumental Analysis of Kitasato University, School of 
Pharmacy for its facilities. 
References and notes 
1. Portoghese, P. S. Trends Pharmacol. Sci. 1989, 10, 230. 
2. Portoghese, P. S.; Sultana, M.; Takemori, A. E. J. Med. Chem. 
1990, 33, 1714. 
3. Sofuoglu, M.; Portoghese, P. S.; Takemori, A. E. J. Pharmacol. 
Exp. Ther. 1991, 257, 676. 
4. Portoghese, P. S.; Sultana, M.; Nagase, H.; Takemori, A. E. Eur. J. 
Pharmacol. 1992, 218, 195. 
5. Dondio, G.; Ronzoni, S.; Eggleston, D.S.; Artico, M.; Petrillo, P.; 
Petrone, G.; Visentin, L.; Farina, C. Vecchietti, V.; Clarke, G.D. J. 
Med. Chem. 1997, 40, 3192. 
6. Nagase, H.; Kawai, K.; Hayakawa, J.; Wakita, H.; Mizusuna, A.; 
Matsuura, H.; Tajima, C.; Takezawa, Y.; Endo, T. Chem. Pharm. 
Bull. 1998, 46, 1695. 
7. Nagase, H.; Osa, Y.; Nemoto, T.; Fujii, H.; Imai, M.; Nakamura, 
T.; Kanemasa, T.; Kato, A.; Gouda, H.; Hirono, S. Bioorg. Med. 
Chem. Lett. 2009, 19, 2792. 
8. Nagase, H.; Nemoto, T.; Matsubara, A.; Saito, M.; Yamamoto, N.; 
Osa, Y.; Hirayama, S.; Nakajima, M.; Nakao, K.; Mochizuki, H.; 
Fujii, H. Bioorg. Med. Chem. Lett. 2010, 20, 6302. 
9. Portoghese, P. S.; Nagase, H.; Lipkowski, A. W.; Larson, D. L.; 
Takemori, A. E. J. Med. Chem. 1988, 31, 836. 
10. Stevene, W.C.; Jones, R. M. Jr.; Subramanian, G.; Metzger, T.G.; 
Ferguson, D.M.; Portoghese, P. S. J. Med. Chem. 2000, 43, 2759. 
11. Nagase, H.; Hayakawa, J.; Kawamura, K.; Kawai, K.; Takezawa, 
Y.; Matsuura, H.; Tajima, C.; Endo, T. Chem. Pharm. Bull. 1998, 
46, 366.  
12. Kawai, K.; Hayakawa, J.; Miyamoto, T.; Imamura, Y.; Yamane, 
S.; Wakita, H.; Fujii, H.; Kawamura, K.; Matsuura, H.; Izumimoto, 
N.; Kobayashi, R.; Endo, T.; Nagase, H. Bioorg. Med. Chem. 2008, 
16, 9188. 
13. Yamamoto, N.; Fujii, H.; Nemoto, T.; Nakajima, R.; Momen, S.; 
Izumimoto, N.; Hasebe, K.; Mochizuki, H.; Nagase, H. Bioorg. 
Med. Chem. Lett. 2011, 21, 4104. 
14. Li, F.; Gaob, L.; Yin, C.; Chen, J.; Liu, J.; Xie, X.; Zhang, A. 
Bioorg. Med. Chem. Lett. 2009, 19, 4603. We also obtained the 
same experimental results at the same time as those.  
15. Granier, S.; Manglik, A.; Kruse, A. C.; Kobilka, T.S.; Thian, F.S.; 
Weis, W. I.; Kobilka, B.K. Nature 2012, 485, 400. 
16. Tsujishita, H.; Hirono, S. J. Comput. Aided Mol. Des. 1997, 11, 
305. 
17. Docking was done with the induced fit docking protocol of 
Schrödinger Suite 2010. 
18. Massova, I.; Kollman, P. A. Perspect. Drug Discov. Des. 2000, 18, 
113. 
19. Kollman, P. A.; Massova, I.; Reyes, C.; Kuhn, B.; Huo, S.; Chong, 
L.; Lee, M.; Lee, T.; Duan, Y.; Wang, W.; Donini, O.; Cieplak, P.; 
Srinivasan, J.; Case, D. A.; Cheatham, T. E., 3rd. Acc. Chem. Res. 
2000, 33, 889. 
20. The stable conformers of trans-isomers of morphinans are 
expected to be extended conformations and could fit to delta 
receptor. On the other hand, the stable ones of cis-compounds like 
propellanes may be bent form and could not fit to. 
21. Cheng, C. –C.; Yan, S. –J. In Org. React.; Dauben, W. G., Ed.; 
John Wiley & Sons. Inc.: Canada, 1982; Vol. 28, pp 37–201. 
22. Greiner, E.; Folk, J. E.; Jacobson, A. E.; Rice, K. C. Bioorg. Med. 
Chem. 2004, 12, 233. 
